September 7, 2010

US unveils AquAdvantage GM Salmon

The Veterinary Medical Advisory Committee (VMAC) of the Food and Drug Administration (FDA) has announced that the FDA has essentially found the AquAdvantage genetically modified (GM) salmon to be equivalent to other non-transgenic salmon.

This is another milestone for AquaBounty Technologies towards its pending approval of its AquAdvantage salmon product from the FDA. AquAdvantage Salmon is a genetically-engineered Atlantic salmon with a rapid-growth phenotype that has been developed over the past 15 years.

In an Environmental Assessment, AquAdvantage salmon are highly unlikely to cause any significant effects on the environment - inclusive of the global commons, foreign nations and stocks of wild Atlantic salmon, according to the VMAC.

On September 19-20, the VMAC will meet to discuss and vote on AquaBounty's application.